Tesofensine
Sources
registry, as of 2013-04-22Stale
https://clinicaltrials.gov/study/NCT00394667
Effect of Tesofensine on Weight Reduction in Patients With Obesity.. Overall status COMPLETED. Phases PHASE2. Lead sponsor NeuroSearch A/S. Enrollment 200. Conditions Obesity. Purpose: To evaluate the efficacy on weight reduction, metabolic parameters and safety of tesofensine versus placebo in obese patients
ClinicalTrials.gov NCT00394667 protocol and results modules
registry, as of 2011-07-04Stale
https://clinicaltrials.gov/study/NCT00481104
Evaluation of Long Term Safety of Tesofensine in Patients With Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor NeuroSearch A/S. Enrollment 140. Conditions Obesity. Purpose of the study is to evaluate the long term safety of tesofensine in obese patients
ClinicalTrials.gov NCT00481104 protocol and results modules
registry, as of 2008-03-05Stale
https://clinicaltrials.gov/study/NCT00428415
Effect of Tesofensine on Energy Balance in Humans.. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor NeuroSearch A/S. Enrollment 32. Conditions Obesity. Purpose: To evaluate the effect of tesofensine on energy balance
ClinicalTrials.gov NCT00428415 protocol and results modules
registry, as of 2024-02-13Stale
https://clinicaltrials.gov/study/NCT03845075
48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO). Overall status COMPLETED. Phases PHASE2. Lead sponsor Saniona. Enrollment 21. Conditions Hypothalamic Injury-induced Obesity (HIO). Double-blind, randomized, placebo-controlled, single- center study followed by an open-label extension period. • The study will have two parts: * Part 1: 24 weeks double-blind treatment (DB), followed by * Part 2: 24 weeks open-label extension (OLE) - all subjects still partici deaths Placebo 0 nausea Placebo 2 vomiting Placebo 2 diarrhoea Placebo 2 deaths Placebo -> Tesofensine/Metoprolol 0 nausea Placebo -> Tesofensine/Metoprolol 0 vomiting Placebo -> Tesofensine/Metoprolol 0 diarrhoea Placebo -> Tesofensine/Metoprolol 0
ClinicalTrials.gov NCT03845075 protocol and results modules
publication, as of 2010-01-22Stale
https://pubmed.ncbi.nlm.nih.gov/19777399/
Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Tesofensine, a monoamine reuptake inhibitor, is under development by NeuroSearch A/S for the potential treatment of obesity. In vitro, the compound p
PMID 19777399